Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

Canada's Apotex filed for approval of a Neulasta biosimilar in December and has also filed for approval of a Neupogen biosimilar that could be on the US market before the end of the year.

Some Michigan hospitals are marking up prices by thousands of dollars above what they pay manufacturers for certain prescription drugs, according to a new report from the Michigan Health Purchasers ...

It's a very competitive marketplace as we play in this -- this Neulasta biosimilar long-acting GCSF space. And there could be new entrants that enter as we go through this year that could also ...

Biosimilars are like generic drugs ... They also may prescribe a medication such as Neulasta (pegfilgrastim). This medication can help increase neutrophils if you have a higher risk of neutropenia.

The Global On Body Drug Delivery Devices Market is projected to grow from $40.54B in 2024 to $82.74B by 2033, expanding at a CAGR of 8.6% during 2025-2033. Driven by rising chronic diseases and demand ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Since 2006, the European Union has approved 23 biosimilars, 16 of which are used in cancer; examples of recent approvals are CT-P10 and L01XC02, which are biosimilars of rituximab. 26 Worldwide, more ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

As per the latest analysis, the biosimilar and biologics market value is estimated to reach USD 520.9 billion in 2024. Global sales of biosimilars and biologics will likely increase at 7.6% CAGR ...

Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Bevacizumab - Biosimilar Insight, 2025" has been added to ResearchAndMarkets.com's offering. Bevacizumab - Biosimilar Insight, 2025 offers an in-depth ...